Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

What additional medications were you taking at the time?

Was Gemfibrozil (Lopid) taken while taking Baycol?

Has Rhabdomyolysis been diagnosed?

Have any of the following side effects occurred?

Please further describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Bayer Reaches Deal On Cholesterol Drug

Mar 10, 2004 | AP German drug maker Bayer AG has reached an agreement with most of its insurers on coverage of around $1.2 billion for litigation related to the 2001 withdrawal of a cholesterol-lowering drug.

In a statement Tuesday night, Bayer also said it had put aside 300 million euros ($369 million) in its 2003 fiscal year to cover additional settlements and defense costs. The insurers "had previously proceeded only on a provisional basis," the company said.

Bayer pulled Lipobay, marketed as Baycol in the United States, in August 2001 after it was linked to a rare muscle-wasting syndrome and about 100 patient deaths.

On Tuesday, the Leverkusen-based company said it has now reached 2,224 cases related to the drug, paying out $842 million without admitting liability.

Another 9,948 cases were pending in the United States as of March 5, Bayer said.

"Where facts have been developed in the course of the litigation, it so far appears that the vast majority of plaintiffs did not suffer serious side-effects," its statement said.

Other articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo